Johannes Jacob Piete Kastelein Sells 6,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 6,000 shares of the business’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $33.25, for a total transaction of $199,500.00. Following the transaction, the insider owned 73,481 shares in the company, valued at $2,443,243.25. This represents a 7.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS opened at $35.80 on Friday. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $42.00. The company has a market capitalization of $4.06 billion, a P/E ratio of -17.46 and a beta of 0.07. The company has a 50-day simple moving average of $36.80 and a 200 day simple moving average of $29.88.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The business had revenue of $0.35 million for the quarter, compared to analyst estimates of $4.54 million. As a group, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds have recently bought and sold shares of the business. CIBC Bancorp USA Inc. acquired a new stake in NewAmsterdam Pharma in the 3rd quarter worth about $886,000. Polar Capital Holdings Plc increased its holdings in shares of NewAmsterdam Pharma by 15.6% during the third quarter. Polar Capital Holdings Plc now owns 2,911,634 shares of the company’s stock worth $82,807,000 after purchasing an additional 393,855 shares during the period. HighVista Strategies LLC raised its position in shares of NewAmsterdam Pharma by 65.1% in the third quarter. HighVista Strategies LLC now owns 31,831 shares of the company’s stock valued at $905,000 after buying an additional 12,557 shares in the last quarter. Fred Alger Management LLC boosted its stake in shares of NewAmsterdam Pharma by 87.2% in the third quarter. Fred Alger Management LLC now owns 41,264 shares of the company’s stock valued at $1,174,000 after buying an additional 19,227 shares during the period. Finally, Duquesne Family Office LLC grew its position in NewAmsterdam Pharma by 131.2% during the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after buying an additional 1,091,525 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Leerink Partners reaffirmed an “outperform” rating and set a $55.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday. Citigroup raised their target price on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, October 17th. Stifel Nicolaus lifted their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Needham & Company LLC increased their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Royal Bank Of Canada boosted their price objective on NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus target price of $46.73.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.